Advanced aggressive fibromatosis: Effective palliation with chemotherapy

Acta Oncologica

Volumn 50, Issue 3, 2011, Pages 455-461

  Constantinidou, Anastasia ^a   Jones, Robin L ^a   Scurr, Michelle ^a   Al Muderis, Omar ^a   Judson, Ian ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DICLOFENAC; DOXORUBICIN; ETOPOSIDE; HYDROXYUREA; IFOSFAMIDE; IMATINIB; METHOTREXATE; NAVELBINE; PREDNISOLONE; SULINDAC; TAMOXIFEN; TOREMIFENE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED AGGRESSIVE FIBROMATOSIS; ADVANCED CANCER; ANALGESIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INTOXICATION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEMALE; FIBROMATOSIS; FOLLOW UP; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PERINEUM; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PLANTAR PALMAR ERYTHEMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; UNSPECIFIED SIDE EFFECT; VOMITING;

ABDOMINAL NEOPLASMS; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; FIBROMATOSIS, AGGRESSIVE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM INVASIVENESS; PALLIATIVE CARE; POLYETHYLENE GLYCOLS; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINBLASTINE; YOUNG ADULT;

EID: 79952661775     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.509105     Document Type: Article

References (24)

1. Alman BA, Pajerski ME, Diaz-Cano S, Corboy K, Wolfe HJ. Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder. Diagn Mol Pathol 1997;6:98-101. (Pubitemid 27155030)
2. Bauernhofer T, Stöger H, Schmid M, Smola M, Gürtl-Lackner B, Höfler G, et al. Sequential treatment of recurrent mesenteric desmoid tumor. Cancer 1996;77:1061-5. (Pubitemid 26080895)
3. Tejpar S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999;18: 6615-20.
4. Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 1997;151:329-34. (Pubitemid 27330053)
5. Gronchi A, Casali PG, Mariani L, Lo Vullo S, Colecchia M, Lozza L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: A series of patients surgically treated at a single institution. J Clin Oncol 2003;21:1390-7. (Pubitemid 46606421)
6. Lev D, Kotilingam D, Wei C, Ballo MT, Zagars GK, Pisters PW, et al. Optimizing treatment of desmoids tumors. J Clin Oncol 2007;25:1785-91.
7. Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: Prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999;17:158-67. (Pubitemid 29022389)
8. Nuyttens JJ, Rust PF, Thomas CR, Turrisi AT, 3rd. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoids tumors. A comparative review of 22 articles. Cancer 2000;88:1517-23. (Pubitemid 30183134)
9. Sherman NE, Romsdahl M, Evans H, Zagars G, Oswald MJ. Desmoid tumors: A 20-year radiotherapy experience. Int J Radiat Oncol Biol Phys 1990;19:37-40. (Pubitemid 20239782)
10. Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS. The pharmacological treatment of aggressive fibromatosis: A systematic review. Ann Oncol 2003;14:181-90. (Pubitemid 36305427)
11. Patel SR, Benjamin RS. Desmoid tumors respond to chemotherapy: Defying the dogma in oncology. J Clin Oncol 2006;24:11-2. (Pubitemid 46630487)
12. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004;100:612-20. (Pubitemid 38128287)
13. Dufresne A, Penel N, Salas S, et al. Updated outcome with long-term follow-up of imatinib for the treatment of progressive or recurrent aggressive fibromatosis (desmoids tumor): A FNCLCC/French Sarcoma Group phase II trial abstract 10518.. J Clin Oncol 2009;27:15s.
14. Gega M, Yanagi H, Yoshikawa R, Noda M, Ikeuchi H, Tsukamoto K, et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoids tumors in association with familial adenomatous polyposis. J Clin Oncol 2006;24:102-5. (Pubitemid 46630500)
15. Hartley JA. Alkylating agents, in Souhami R, Tannock I, Hohenberger P, et al. Oxford Textbook of Oncology. 2 nd ed. New York, NY: Oxford University Press Inc; 2002.
16. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C, et al. Abrogating chemotherapyinduced myelosuppression by recombinant granulocytemacrophage colony-stimulating factor in patients with sarcoma: Protection at the progenitor cell level. J Clin Oncol 1992; 10:1266-77.
17. Weiss AJ, Lackman RD. Low-dose chemotherapy of desmoids tumors. Cancer 1989;64:1192-4.
18. Azzarelli A, Gronchi A, Bertulli R, Tesoro JD, Baratti D, Pennacchioli E, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 2001;92:1259-64.
19. Skapek SX, Hawk BJ, Hoffer FA, Dahl GV, Granowetter L, Gebhardt MC, et al. Combination chemotherapy using vinblastine and methotrexate for the treatment of pro gressive desmoid tumor in children. J Clin Oncol 1998;16:3021-7. (Pubitemid 28417422)
20. Pilz T, Pilgrim TB, Bisogno G, Knietig R, Koscielniak E, Carli M, et al. Chemotherapy in fibromatoses of childhood and adolescence: Results from the Cooperative soft tissue sarcoma study (CWS) and the Italian Cooper ative study group (ICG-AIEOP). Klin Padiatr 1999;211:291-5. (Pubitemid 29364770)
21. Okuno SH, Edmonson JH. Combination chemotherapy for desmoid tumors. Cancer 2003;97:134-5.
22. Wehl G, Rossler J, Otten JE, Boehm N, Uhl M, Kontny U, et al. Response of progressive fibromatosis to therapy with liposomal doxorubicin. Onkologie 2004;27:526-52.
23. Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Pegylated liposomal doxorubicin, an effective, well tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer 2009;45:2930-4.
24. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.